152 related articles for article (PubMed ID: 30216522)
1. Granulomatous dermatitis secondary to vemurafenib in a child with Langerhans cell histiocytosis.
Chen L; Hsi AC; Kothari A; Dehner LP; Hayashi RJ; Coughlin CC
Pediatr Dermatol; 2018 Nov; 35(6):e402-e403. PubMed ID: 30216522
[TBL] [Abstract][Full Text] [Related]
2. BRAF Inhibitor-Associated Granulomatous Dermatitis: A Report of 3 Cases.
Hui Ong EL; Sinha R; Jmor S; Fearfield L
Am J Dermatopathol; 2019 Mar; 41(3):214-217. PubMed ID: 30601209
[TBL] [Abstract][Full Text] [Related]
3. A case of vemurafenib-induced keratosis pilaris-like eruption.
Wang CM; Fleming KF; Hsu S
Dermatol Online J; 2012 Apr; 18(4):7. PubMed ID: 22559022
[TBL] [Abstract][Full Text] [Related]
4. Circulating cell-free BRAF
Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
[TBL] [Abstract][Full Text] [Related]
5. Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption.
Braunstein I; Gangadhar TC; Elenitsas R; Chu EY
J Cutan Pathol; 2014 Jun; 41(6):539-43. PubMed ID: 24517243
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of multiple vemurafenib-induced keratoacanthomas by topical application of imiquimod cream: Confirmation of clinical clearance by dermoscopy.
Rhee do Y; Won KH; Lee YJ; Won CH; Chang SE; Lee MW
J Dermatolog Treat; 2016 Oct; 27(5):448-9. PubMed ID: 27092864
[TBL] [Abstract][Full Text] [Related]
7. Vemurafenib-induced granuloma annulare.
Lee SB; Weide B; Ugurel S; Mössner R; Enk A; Hassel JC
J Dtsch Dermatol Ges; 2016 Mar; 14(3):305-8. PubMed ID: 26972200
[No Abstract] [Full Text] [Related]
8. Vemurafenib-induced eccrine squamous syringometaplasia.
Lescoat A; Droitcourt C; Stock N; Le Gall F; Dupuy A
Dermatology; 2013; 226(4):362-4. PubMed ID: 23860306
[TBL] [Abstract][Full Text] [Related]
9. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.
Alloo A; Garibyan L; LeBoeuf N; Lin G; Werchniak A; Hodi FS; Flaherty KT; Lawrence DP; Lin JY
Arch Dermatol; 2012 Mar; 148(3):363-6. PubMed ID: 22431777
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
Sinha R; Larkin J; Gore M; Fearfield L
Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
[TBL] [Abstract][Full Text] [Related]
11. Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor.
Gandolfi L; Adamo S; Pileri A; Broccoli A; Argnani L; Zinzani PL
J Natl Compr Canc Netw; 2015 Jun; 13(6):715-8. PubMed ID: 26085387
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous adverse events in children treated with vemurafenib for refractory BRAF
Tardieu M; Néron A; Duvert-Lehembre S; Amine Larabi I; Barkaoui M; Emile JF; Seigneurin A; Boralevi F; Donadieu J
Pediatr Blood Cancer; 2021 Sep; 68(9):e29140. PubMed ID: 34109735
[TBL] [Abstract][Full Text] [Related]
13. Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.
Lheure C; Kramkimel N; Franck N; Laurent-Roussel S; Carlotti A; Queant A; Goldwasser F; Avril MF; Dupin N
Dermatology; 2015; 231(4):378-84. PubMed ID: 26452227
[TBL] [Abstract][Full Text] [Related]
14. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
Haroche J; Cohen-Aubart F; Emile JF; Maksud P; Drier A; Tolédano D; Barete S; Charlotte F; Cluzel P; Donadieu J; Benameur N; Grenier PA; Besnard S; Ory JP; Lifermann F; Idbaih A; Granel B; Graffin B; Hervier B; Arnaud L; Amoura Z
J Clin Oncol; 2015 Feb; 33(5):411-8. PubMed ID: 25422482
[TBL] [Abstract][Full Text] [Related]
15. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
16. [Successful drug desensitization after vemurafenib-induced rash].
Klossowski N; Kislat A; Homey B; Gerber PA; Meller S
Hautarzt; 2015 Apr; 66(4):221-3. PubMed ID: 25698338
[TBL] [Abstract][Full Text] [Related]
17. Vemurafenib-induced pityriasis amiantacea: a case report.
Bilgiç Ö
Cutan Ocul Toxicol; 2016 Dec; 35(4):329-31. PubMed ID: 26513697
[TBL] [Abstract][Full Text] [Related]
18. Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation.
Charles J; Beani JC; Fiandrino G; Busser B
J Am Acad Dermatol; 2014 Sep; 71(3):e97-9. PubMed ID: 25128147
[No Abstract] [Full Text] [Related]
19. Perianal presentation of Langerhans cell histiocytosis in children.
Tinsa F; Brini I; Kharfi M; Mrad K; Boussetta K; Bousnina S
Gastroenterol Clin Biol; 2010 Jan; 34(1):95-7. PubMed ID: 19864102
[TBL] [Abstract][Full Text] [Related]
20. Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib.
Gebhardt C; Staub J; Schmieder A; Goerdt S; Utikal J
Acta Derm Venereol; 2015 Jan; 95(1):96-7. PubMed ID: 24710689
[No Abstract] [Full Text] [Related]
[Next] [New Search]